What Alzheimer's disease and dementia are
Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60 to 70 per cent of cases. It is a progressive neurodegenerative condition characterised by the accumulation of extracellular beta-amyloid plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, accompanied by chronic neuroinflammation, synaptic loss, and eventual widespread neuronal death. Clinically, Alzheimer’s disease presents with progressive cognitive decline affecting memory, language, executive function, and visuospatial abilities. In the moderate to severe stages, behavioural and psychological symptoms — including agitation, aggression, circadian rhythm disturbances, and psychosis — affect a majority of patients and are a leading cause of carer stress and institutionalisation.
There is no disease-modifying treatment for Alzheimer’s disease. Available medications, including acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine, provide modest symptomatic benefit in some patients. Antipsychotics and benzodiazepines are sometimes used off-label for severe agitation, but carry significant risks in this population, including increased mortality and accelerated cognitive decline.
Cannabis research on Alzheimer’s disease and dementia
No large randomised controlled trial of a cannabinoid preparation for Alzheimer’s disease has been published in any source.
Postmortem and mechanistic evidence
A 2003 study by Benito and colleagues examined postmortem brain tissue from Alzheimer’s patients and found that cannabinoid CB2 receptors and fatty acid amide hydrolase (FAAH), the enzyme that breaks down the endocannabinoid anandamide, are selectively overexpressed in neuritic plaque-associated astrocytes and microglia in the hippocampus and entorhinal cortex (postmortem immunohistochemistry). CB1 receptor expression remained unchanged. The findings suggest that elements of the endocannabinoid system are upregulated at sites of Alzheimer’s pathology, specifically in the glial cells that mediate neuroinflammation.
A 2006 in-vitro study by Eubanks and colleagues demonstrated that THC competitively inhibits acetylcholinesterase (AChE) and, more notably, prevents AChE-induced aggregation of beta-amyloid peptide — the key pathological marker of Alzheimer’s disease (laboratory mechanistic study). Computational modelling revealed that THC binds in the peripheral anionic site of AChE, the region critical for amyloidogenesis. The authors reported that THC was a considerably superior inhibitor of AChE-induced beta-amyloid aggregation compared to the approved Alzheimer’s drugs donepezil and tacrine. This is an in-vitro finding; whether the effect occurs at clinically achievable brain concentrations in humans is unknown.
Animal model and neuroprotective research
A 2008 review by Bisogno and Di Marzo summarised the available data on the endocannabinoid system in Alzheimer’s disease and concluded that endocannabinoids likely represent an endogenous adaptive response aimed at counteracting both the neurochemical and inflammatory consequences of beta-amyloid-induced tau pathology (narrative review). The review noted that the non-psychotropic cannabinoid cannabidiol (CBD) might also exert protective effects through non-cannabinoid-receptor mechanisms, including antioxidant actions.
A 2008 review by Fernandez-Ruiz and colleagues documented that CB2 receptor activation has been linked to delayed progression of neurodegenerative events in experimental models of Alzheimer’s disease, particularly those involving toxic microglial influence on neuronal homeostasis (narrative review). CB2 receptors were identified in microglia and astrocytes in the brain, and CB2-selective agonists — which do not produce psychoactive effects — were proposed as a clinically promising target.
More recent research confirms several of these preclinical directions. A 2026 study by Patil and colleagues used an in-silico approach to screen Cannabis sativa phytochemicals as potential anti-Alzheimer’s agents (computational study). A 2026 in-vitro study found that CBD limited early beta-amyloid-induced glial activation and preserved synaptic integrity in primary mouse hippocampal neuron-glia cultures (PMID 42331352). A 2026 transgenic mouse study combining CBD and THC at a 50:3 ratio in the APPSwe/PS1deltaE9 model found mixed effects on pathology and cognition (PMID 42054867). None of these studies establishes a human treatment effect.
Human clinical evidence
A 2006 open-label pilot study by Walther and colleagues tested dronabinol (synthetic THC, 2.5 mg daily) in six patients with severe dementia — five with Alzheimer’s disease and one with vascular dementia — who were suffering from circadian and behavioural disturbances (human open-label pilot, n=6). After two weeks of treatment, nocturnal motor activity measured by wrist actigraphy was significantly reduced compared to baseline (p=0.028). The Neuropsychiatric Inventory total score improved (p=0.027), as did subscores for agitation, aberrant motor behaviour, and nighttime behaviours (p<0.05). No side effects were observed during the two-week treatment period. This is the smallest possible pilot study and was open-label, meaning both patients and raters knew treatment was being given. The findings are suggestive but cannot be taken as proof of efficacy.
A 2026 systematic review and meta-analysis with Bayesian and sequential trial analyses examined cannabinoid treatments for agitation in Alzheimer’s disease and found that cannabinoid-based therapies have been investigated as potential symptomatic interventions, but the evidence base remains limited (PMID 42315374). A 2026 CADTH review noted that nabilone, a synthetic cannabinoid, may be studied for agitation in some patients with Alzheimer’s disease, but this conclusion was based on one small trial (PMID 42485476).
A 2026 review of cannabinoids in Alzheimer’s disease spanning animal and human evidence concluded that cannabinoids modulate neuroinflammation, synaptic dysfunction, and protein aggregation, but cognitive effects depend critically on cannabinoid composition, dose, and disease stage (PMID 42211879).
Compounds studied for Alzheimer’s disease and dementia
THC has two distinct lines of evidence in Alzheimer’s disease. Mechanistically, the 2006 Eubanks study showed that THC inhibits acetylcholinesterase and prevents AChE-induced beta-amyloid aggregation in vitro — a disease-relevant mechanism that does not depend on cannabinoid receptor activation. Clinically, the 2006 Walther open-label pilot (n=6) found that 2.5 mg dronabinol daily reduced nocturnal agitation and motor activity in severely demented patients over two weeks. Neither finding has been confirmed in a large placebo-controlled trial. The anti-agitation signal is the more clinically immediate line of evidence; the anti-amyloid mechanism remains a laboratory observation.
CBD has been studied for its anti-inflammatory, antioxidant, and neuroprotective properties in Alzheimer’s models. In-vitro evidence shows that CBD limits beta-amyloid-induced glial activation and preserves synaptic integrity. A 50:3 CBD:THC combination has been tested in a transgenic mouse model with mixed results. No human Alzheimer’s trial of CBD alone has been published. CBD’s favourable safety profile relative to THC makes it a candidate for future clinical research in this population.
Caryophyllene is a CB2 receptor agonist. Since CB2 receptors are overexpressed in Alzheimer’s pathology and CB2 activation has been linked to reduced neuroinflammation in preclinical models, caryophyllene has a plausible mechanistic rationale. No human Alzheimer’s study of caryophyllene exists.
Pinene is an acetylcholinesterase inhibitor, sharing a mechanistic property with the approved Alzheimer’s drugs donepezil, rivastigmine, and galantamine. The activity is established in vitro, but pinene has not been tested in any Alzheimer’s model or human study for cognitive outcomes.
Linalool has been studied for sedative and anxiolytic properties in animal models and may be relevant to the agitation and sleep disturbance components of dementia. No human dementia study of linalool exists.
Limits of the evidence for Alzheimer’s disease and dementia
No cannabinoid preparation is an established or licensed treatment for Alzheimer’s disease or any other form of dementia. The human evidence consists of one open-label pilot study of six patients treated for two weeks. The positive signal for agitation reduction in that study is of clinical interest but does not meet the standard for a treatment recommendation.
The in-vitro finding that THC inhibits AChE-induced beta-amyloid aggregation more potently than approved Alzheimer’s drugs does not establish that THC has disease-modifying effects in humans. Laboratory observations at isolated protein targets do not predict clinical efficacy. No disease-modifying human trial of a cannabinoid for Alzheimer’s disease has been published.
The anti-agitation evidence and the disease-modification evidence should not be conflated. It is possible that cannabinoids could reduce behavioural symptoms in dementia without affecting the underlying disease process, or vice versa. Neither pathway has been adequately tested in humans.
Safety data in elderly and medically vulnerable dementia populations are minimal. The cardiovascular effects of THC, the risk of falls and confusion, drug-drug interactions with acetylcholinesterase inhibitors, and the effects of chronic cannabinoid exposure on the ageing brain are largely unknown.
Related conditions
- Parkinson’s disease ; four trials and their safety findings
- Stroke ; cannabis, cerebrovascular risk, and post-stroke recovery research
- ALS/Motor neuron disease ; early research on spasticity and symptom control
- Sleep disorders ; negative CBN trials and modest THC findings
Read next
- THC ; studied in one small trial for nighttime agitation in dementia
- CBD ; examined for neuroprotective and anti-inflammatory effects
- Browse the cannabinoid reference
- Browse the terpene reference
Sources
1. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185(4):524-528. Study record
2. Eubanks LM, Rogers CJ, Beuscher AE, et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Molecular Pharmaceutics. 2006;3(6):773-777. Study record
3. Benito C, Nunez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. Journal of Neuroscience. 2003;23(35):11136-11141. Study record
4. Bisogno T, Di Marzo V. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses. Current Pharmaceutical Design. 2008;14(23):2299-2305. Study record
5. Fernandez-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA. Role of CB2 receptors in neuroprotective effects of cannabinoids. Molecular and Cellular Endocrinology. 2008;286(1-2 Suppl 1):S91-S96. Study record
6. Cannabinoids treatment for agitation in Alzheimer’s disease: a systematic review and meta-analysis with Bayesian and sequential trial analyses. 2026. PMID: 42315374. Study record
7. Cannabidiol limits early Aβ-induced glial activation and preserves synaptic integrity in primary mouse hippocampal neuron-glia cultures. 2026. PMID: 42331352. Study record
8. Cannabinoids in Alzheimer’s disease: animal-human evidence and clinical pharmacology challenges. 2026. PMID: 42211879. Study record
9. Nabilone for behavioural and psychological symptoms of dementia. CADTH. 2026. PMID: 42485476. Study record
